Kymera Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Oct 29, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Oct 29, 2026

KYMR$136.64-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

For the three and nine months ended September 30, 2026 and 2025

(In thousands, except for share and per share amounts)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2026	2025	2026	2025
Collaboration revenue	$—	$2,764	$99,365	$36,341
Operating expenses:
Research and development	$128,509	$74,094	$346,152	$232,737
General and administrative	18,723	17,336	60,207	51,252
Impairment of long-lived assets	—	3,855	—	3,855
Total operating expenses	147,232	95,285	406,359	287,844
Loss from operations	(147,232)	(92,521)	(306,994)	(251,503)
Other income (expense):
Interest and other income	15,295	10,444	44,753	27,413
Interest and other expense	(62)	(98)	(203)	(280)
Total other income	15,233	10,346	44,550	27,133
Net loss	$(131,999)	$(82,175)	$(262,444)	$(224,370)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities	(7,578)	1,222	(16,535)	2,986
Total comprehensive loss	$(139,577)	$(80,953)	$(278,979)	$(221,384)
Net loss	$(131,999)	$(82,175)	$(262,444)	$(224,370)
Net loss per share, basic and diluted	$(1.32)	$(0.94)	$(2.66)	$(2.71)
Weighted average common stock outstanding, basic and diluted	100,097,242	87,300,286	98,612,278	82,653,142

CONDENSED CONSOLIDATED STATEMENTS OF

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.